Galapagos NV (GLPG) IPO Opens up 10%
May 14, 2015 10:39 AM
Today's IPO for Galapagos NV (Nasdaq: GLPG) opened for trading at $46.30 after pricing 6,550,000 new ordinary shares, consisting of 4,996,522 American Depositary Shares at $42.05 per ADS, and 1,533,478 ordinary shares at a price of €37.00 per share, both before underwriting discounts.
In addition, Galapagos has granted the underwriters an option to purchase up to an additional 749,478 new ordinary shares in the form of ADSs and an option to purchase up to an additional 233,021 new ordinary shares, representing 15% of the ordinary shares and ADSs placed in the global offering. This option can be exercised during the 30 day period commencing 14 May2015.
Morgan Stanley, Credit Suisse and Cowen and Company are acting as joint book-running managers, and Nomura and Bryan, Garnier & Co. are acting as co-managers, for the global offering. Morgan Stanley is acting as stabilization agent on behalf of the underwriters.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos reported good activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.
Categories
IPOs
Next Articles
Galapagos NV (GLPG) Prices 5M ADS, 1.5M Ordinary Share IPO
May 14, 2015 9:26 AM
Bryan, Garnier & Co Announces the Successful $275m IPO for Galapagos NV, the Largest Nasdaq IPO of European Biotech
May 14, 2015 6:57 AM
Galapagos (Nasdaq: GLPG) to Ring The Nasdaq Stock Market Opening Bell
May 14, 2015 6:00 AM
Galapagos raises $275 million gross proceeds with NASDAQ IPO
May 13, 2015 11:23 PM